The effect of “ conventional medicine,blood sugaron the Insulin resistance of patients with Diabetes Mellitus type II

The effect of “ conventional medicine,blood sugar”(combination of powder of Urtica dioica leaf %20,powder of Morus nigra leaf %10,powder of Allium Sativum %20 ,powder of Trigonella foenum-graceum or Fenugreek seed%20 ,powder of Junglans Regia leaf %20 ,powder of Cinnamomum Zeylanicum %10)on the Insulin resistance of patients with Diabetes Mellitus type II

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016011826097N1

Enrollment

Registered

2017-05-02

Start date

2014-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabet mellitus type2. non-Insulin-dependent diabetes mellitus

Interventions

Intervention 1: The experiment group: Diabites, an herbal medicine for the treatment of diabetes, is provided in 750 mg capsules (licensed by Iranian Ministry of Health

produced and manufactured by Booalidaroo Company, Qom, Iran). The cases in the experiment group received Diabites 3 times a day, each time 1 capsule, in addition to the previously prescribed conventio

Treatment - Drugs

Placebo

The experiment group: Diabites, an herbal medicine for the treatment of diabetes, is provided in 750 mg capsules (licensed by Iranian Ministry of Health

The control group: The placebo (750 mg capsules similar to the interventional herbal medicine) was given to the control group cases 3 times a day, each time 1 capsule, in addition to the previously pr

Eligibility

Sex/Gender

All

Age

25 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:the age range of 25 to 70 years for both genders, FBS >130 mg/dL and 2hppBS >180 mg/dL, uncontrolled BS with two decreased BS oral drug in patient the candidates for insulin injection, but had no willingness to inject. Exclusion criteria: cardiovascular,kidney and liver disease; pregnancy; breast feeding

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).;HbA1c. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).;HOMA-IR. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).	—

Measure

Time frame

FBS. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).;HbA1c. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).;HOMA-IR. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).

—

Secondary

Measure	Time frame
TG. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).;CHOL. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).;LDL. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).;HDL. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).	—

Measure

Time frame

TG. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).;CHOL. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).;LDL. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).;HDL. Timepoint: Before intervention, after 6 weeks, after intervention(after 12 weeks). Method of measurement: blood test (Mg per deciliter).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJamshid Vafaeemanesh

Qom University of Medical Sciences

J.vafaeemanesh@muq.ac.irJvafaeemanesh@yahoo.com+98 25 3320 9071

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026